Report 2006-108 Recommendation 3 Responses

Report 2006-108: California Institute for Regenerative Medicine: It Has a Strategic Plan, but It Needs to Finish Developing Grant-Related Policies and Continue Strengthening Management Controls to Ensure Policy Compliance and Cost Containment (Release Date: February 2007)

Recommendation #3 To: Regenerative Medicine, California Institute for

The committee should monitor the effectiveness of its policy to make institute-funded patented inventions readily accessible on reasonable terms to other grantee organizations for noncommercial purposes to ensure that it does not inhibit the advance of stem cell research.

1-Year Agency Response

The institute points to recently-adopted regulations that are intended to promote rapid advancement of the field. These regulations generally require institute grantees to give other researchers access to biomedical materials discussed in published research, at no more than cost, for research purposes. The institute reports that it monitors compliance with these regulations by requiring grantees to submit annual progress reports that identify publications and licensed patented inventions, as well as any requests for access by other scientists for noncommercial research purposes. (See 2009-406, p. 230)

California State Auditor's Assessment of 1-Year Status: Fully Implemented

All Recommendations in 2006-108

Agency responses received after June 2013 are posted verbatim.